Here’s what drug makers don’t want you to know about PBMs
Pharmacy benefit managers shield patients from higher drug prices, but drug makers don’t want you to know that.
Read MoreClinically Speaking: Boosting Biosimilars Competition and Savings
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Read MoreExpress Scripts Adds Three Biosimilars to Largest Formulary to Promote Competition and Advance Affordability, Choices for Patients
Read More
Experts share strategies for improving health care experiences and outcomes
Panelists at the Evernorth Outcomes conference discussed ways they have approached some of today’s biggest challenges in the health care industry – including fragmented care systems, pharmacy costs, a...
Read MoreExpress Scripts launches new initiative to expand rural health care access through partnerships with independent pharmacies
Express Scripts announced key efforts to expand access to health care in rural communities through partnerships with independent pharmacies across the U.S.
Read MoreWhat to look for in the upcoming gene therapy pipeline
As the gene therapy landscape continues to evolve, plan sponsors should familiarize themselves with the tools and strategies necessary to navigate the future of these game-changing treatments.
Read MoreExpress Scripts Further Advances Transparency and Affordability for Consumers and Clients
Express Scripts, the pharmacy benefits management business of Evernorth, a subsidiary of The Cigna Group (NYSE: CI), today announced several actions to further evolve its pharmacy benefit management (...
Read MoreImproving Access to the Most Up-to-Date Cancer Care
Cancer treatment can be scary and complicated. Express Scripts is partnering with Labcorp to help ensure members have access to targeted and personalized treatments.
Read MoreDrug Lists 101 – Supporting Access to Safe and Effective Medications
Drug formularies are critical to combat the estimated $16 billion wasted each year on low value drugs that do not improve health outcomes.
Read MoreStrategies to Encourage the Adoption of Biosimilars
Here are three ways plan sponsors can promote and manage the appropriate use of biosimilars to improve drug affordability and access for members.
Read More